United States· US:69097-361_6cf78fd3-5be6-412c-acdf-f599efaf0654
grisofulvin
A medicinal product containing griseofulvin, registered in United States by Cipla USA Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- GRISEOFULVIN
- Manufacturer
- Cipla USA Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1169097-361-08
- ndc116909736108120 mL in 1 BOTTLE (69097-361-08)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Griseofulvin in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomFulsovin 125mg/5ml oral suspensionKappin Ltd
- FinlandFulcinAstraZeneca UK Limited
- ItalyFULCIN 125*20 cpr 125 mgSIT LABORATORIO FARMAC. Srl
- NorwayFulcinLaboratorio Farmaceutico S.I.T. Srl
- IrelandGriseofulvin 500 mg film-coated tabletsBrown & Burk IR Limited
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Cyprus · Griseofulvin Remedica, Medofulvin
- France · Grisefuline
- United Kingdom (Northern Ireland) · Griseofulvin Brown & Burk Uk, Grisol
- Ireland · Griseofulvin Brown & Burk Ir
- Italy · Fulcin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7c5ea45f-58d2-4bfb-82dc-16b0d02be977 GET /v1/drugs/7c5ea45f-58d2-4bfb-82dc-16b0d02be977?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "125",
"substance": "GRISEOFULVIN",
"productndc": "69097-361",
"dosage_form": "SUSPENSION",
"dea_schedule": null,
"strength_unit": "mg/5mL",
"application_number": "ANDA065354",
"marketing_category": "ANDA"
}See everything about griseofulvin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.